Case Reports Open access

Multisystemic inflammatory syndrome related to COVID-19, with latent tuberculosis in bone marrow, and satisfactory response to tocilizumab, in a 7-year-old boy

Authors

Published
7 February 2022
Section
Case Reports
DOI
10.4081/reumatismo.2021.1448

Abstract

Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) or multisystem inflammatory syndrome in children (MIS-C) is a new acute-onset systemic inflammatory disease, which mainly affects children. Latent tuberculosis infection (LTBI) is characterized by the presence of immune sensitization to Mycobacterium tuberculosis (MTB) in the absence of any clinical or radiological evidence of active disease. We present a child with MIS-C related to COVID-19, with latent TB in the bone marrow, and satisfactory response to tocilizumab. It is important to pay attention in the investigation of TB cases in countries with a high prevalence of tuberculosis, especially when opting for immunusuppression.

Keywords

References

  1. OPS (Organización Panamericana de la Salud). La OMS declara que el nuevo brote de coronavirus es una emergencia de salud pública de importancia internacional; 30 Jan 2020. Available from: https://www.paho.org/es/noticias/30-1-2020-oms-declara-que-nuevo-brote-coronavirus-es-emergencia-salud-publica-importancia
  2. Samudrala PK, Kumar P, Choudhary K, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020; 883: 173375. DOI: https://doi.org/10.1016/j.ejphar.2020.173375
  3. World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19: Scientific Brief. 2020. Available from: https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
  4. Royal College of Paediatrics and Child Health. Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf
  5. Centers for Disease Control and Prevention. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C). Available from: https://www.cdc.gov/mis/hcp/index.html
  6. Fernández-Sarmiento J, De Souza D, Jabornisky R, et al. Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): a narrative review and the viewpoint of the Latin American Society of Pediatric Intensive Care (SLACIP) Sepsis Committee BMJ Paediatrics Open 2021;5:e000894. DOI: https://doi.org/10.1136/bmjpo-2020-000894
  7. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021; 73: e13-e29. DOI: https://doi.org/10.1002/art.41616
  8. McArdle AJ, Vito O, Patel H, et al. BATS Consortium. Treatment of multisystem inflammatory syndrome in children. N Engl J Med. 2021 [Epub ahead of print]. DOI: https://doi.org/10.1056/NEJMoa2102968
  9. Mayito J, Andia I, Belay M, et al. Anatomic and cellular niches for mycobacterium tuberculosis in latent tuberculosis infection. J Infect Dis. 2019; 219: 685-94.
  10. Bandyopadhyay A, Palepu S, Bandyopadhyay K, Handu S. COVID-19 and tuberculosis co-infection: a neglected paradigm. Monaldi Arch Chest Dis. 2020; 90(3). DOI: https://doi.org/10.4081/monaldi.2020.1437
  11. Thomas TA. Tuberculosis in children. Pediatr Clin North Am. 2017; 64: 893-909. DOI: https://doi.org/10.1016/j.pcl.2017.03.010
  12. Carvalho I, Goletti D, Manga S, et al. Managing latent tuberculosis infection and tuberculosis in children. Pulmonology. 2018; 24: 106-14. DOI: https://doi.org/10.1016/j.rppnen.2017.10.007
  13. Godfred-Cato S, Bryant B, Leung J, et al. California MIS-C Response Team. COVID-19-associated multisystem inflammatory syndrome in children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 1074-80. DOI: https://doi.org/10.15585/mmwr.mm6932e2
  14. Cattalini M, Taddio A, Bracaglia C, et al. Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics. Ital J Pediatr. 2021; 47: 24. DOI: https://doi.org/10.1186/s13052-021-00980-2
  15. Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr. 2021; 18: 1-16. DOI: https://doi.org/10.1101/2020.08.17.20173641
  16. Jonat B, Gorelik M, Boneparth A, et al. Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a children’s hospital in New York City: patient characteristics and an institutional protocol for evaluation, management, and follow-up. Pediatr Crit Care Med. 2021; 22: e178-91. DOI: https://doi.org/10.1097/PCC.0000000000002598
  17. McIntosh AM, Tong S, Deakyne SJ, et al. Validation of the vasoactive-inotropic score in pediatric sepsis. Pediatr Crit Care Med. 2017; 18: 750-7. DOI: https://doi.org/10.1097/PCC.0000000000001191
  18. World Health Organization. Global tuberculosis report; 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf
  19. World Health Organization. Global tuberculosis report; 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf
  20. Tadolini M, Codecasa LR, García-García JM, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Resp J. 2020; 2001398. DOI: https://doi.org/10.1183/13993003.02328-2020
  21. Mayito J, Andia I, Belay M, et al. Anatomic and Cellular Niches for Mycobacterium tuberculosis in latent tuberculosis infection. J Infect Dis. 2019; 219: 685-94. DOI: https://doi.org/10.1093/infdis/jiy579
  22. Batu ED, Özen S. Implications of COVID-19 in pediatric rheumatology. Rheumatol Int. 2020; 40: 1193-213. DOI: https://doi.org/10.1007/s00296-020-04612-6
  23. Lobo N, Brooks NA, Zlotta AR, et al. 100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021; 18: 611-22. DOI: https://doi.org/10.1038/s41585-021-00481-1
  24. Miller A, Reandelar MJ, Fasciglione K, et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv. 2020. [Epub ahead of print]. DOI: https://doi.org/10.1101/2020.03.24.20042937
  25. Torun S, Ozkaya S, Şen N, et al. The Relationship between COVID-19 severity and Bacillus Calmette-Guérin (BCG)/Mycobacterium tuberculosis exposure history in healthcare workers: a multi-center study. Pathog Glob Health. 2021: 1-7. [Epub ahead of print]. DOI: https://doi.org/10.1080/20477724.2021.1927605
  26. Chaisemartin C, de Chaisemartin L. Bacille Calmette-Guérin vaccination in infancy does not protect against coronavirus disease 2019 (COVID-19): evidence from a natural experiment in Sweden. Clin Infect Dis. 2021; 72: e501-5. DOI: https://doi.org/10.1093/cid/ciaa1223
  27. Patella V, Delfino G, Bruzzese D, et al. The bacillus Calmette-Guérin vaccination allows the innate immune system to provide protection from severe COVID-19 infection. Proc Natl Acad Sci U S A. 2020; 117: 25205-6. DOI: https://doi.org/10.1073/pnas.2015234117

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.